IMCT-10A PHASE I DOSE ESCALATION STUDY TO TEST THE SAFETY OF INTRATUMORAL ADOPTIVE IMMUNE THERAPY WITH AlloCTL IN RECURRENT GLIOMA PATIENTS

Volume: 17
Published: Nov 1, 2015
Abstract
In a Phase 1 dose escalation study we evaluated the safety, feasibility, toxicity, and survival of patients treated with allogeneic cytotoxic T lymphocytes and recombinant IL-2 (alloCTL, rIL-2) infusion administered to the resection cavity of patients with recurrent glioma (WHO grade III or IV). AlloCTL are generated when gamma-irradiated lymphoblasts from the brain tumor patient stimulate the proliferation of peripheral blood mononuclear cells...
Paper Details
Title
IMCT-10A PHASE I DOSE ESCALATION STUDY TO TEST THE SAFETY OF INTRATUMORAL ADOPTIVE IMMUNE THERAPY WITH AlloCTL IN RECURRENT GLIOMA PATIENTS
Published Date
Nov 1, 2015
Volume
17
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.